CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $135.00 per share for the 12-month period ending 2025-12-27, per its 10-K filed 2026-02-18.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-02-18
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $135.00, a 35.96% decline from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $210.81, a 8.51% increase from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $194.27, a 20.07% decline from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $243.05, a 27.91% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2025-12-27 | $135.00 10-K · filed 2026-02-18 |
| 2024-12-28 | $210.81 10-K · filed 2025-02-19 |
| 2023-12-30 | $194.27 10-K · filed 2024-02-14 |
| 2022-12-31 | $243.05 10-K · filed 2023-02-22 |
| 2021-12-25 | $337.13 10-K · filed 2022-02-16 |
| 2020-12-26 | $178.79 10-K · filed 2021-02-17 |
| 2019-12-28 | $144.42 10-K · filed 2020-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |